Stock Research for TROV

TROV

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

TROV Stock Chart & Research Data

The TROV chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the TROV chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


TROV Due diligence Resources & Stock Charts

The TROV stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View TROV Detailed Price Forecast - CNN Money CNN View TROV Detailed Summary - Google Finance
Yahoo View TROV Detailed Summary - Yahoo! Finance Zacks View TROV Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View TROV Trends & Analysis - Trade-Ideas Barrons View TROV Major Holders - Barrons
NASDAQ View TROV Call Transcripts - NASDAQ Seeking View TROV Breaking News & Analysis - Seeking Alpha
Spotlight View TROV Annual Report - CompanySpotlight.com OTC Report View TROV OTC Short Report - OTCShortReport.com
TradeKing View TROV Fundamentals - TradeKing Charts View TROV SEC Filings - Bar Chart
WSJ View Historical Prices for TROV - The WSJ Morningstar View Performance/Total Return for TROV - Morningstar
MarketWatch View the Analyst Estimates for TROV - MarketWatch CNBC View the Earnings History for TROV - CNBC
StockMarketWatch View the TROV Earnings - StockMarketWatch MacroAxis View TROV Buy or Sell Recommendations - MacroAxis
Bullish View the TROV Bullish Patterns - American Bulls Short Pains View TROV Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View TROV Stock Mentions - StockTwits PennyStocks View TROV Stock Mentions - PennyStockTweets
Twitter View TROV Stock Mentions - Twitter Invest Hub View TROV Investment Forum News - Investor Hub
Yahoo View TROV Stock Mentions - Yahoo! Message Board Seeking Alpha View TROV Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for TROV - SECform4.com Insider Cow View Insider Transactions for TROV - Insider Cow
CNBC View TROV Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for TROV - OTC Markets
Yahoo View Insider Transactions for TROV - Yahoo! Finance NASDAQ View Institutional Holdings for TROV - NASDAQ


Stock Charts

FinViz View TROV Stock Insight & Charts - FinViz.com StockCharts View TROV Investment Charts - StockCharts.com
BarChart View TROV Stock Overview & Charts - BarChart Trading View View TROV User Generated Charts - Trading View




Latest Financial News for TROV


Is TrovaGene Inc (NASDAQ:TROV) A Healthcare Industry Laggard Or Leader?
Posted on Tuesday September 18, 2018

TrovaGene Inc (NASDAQ:TROV), a US$14.2m small-cap, is a healthcare company operating in an industry, which continues to be affected by the sustained economic uncertainty and structural trends, such as anRead More...


Trovagene Announces Participation at The MicroCap Conference on October 1st and 2nd at the Essex House in New York City
Posted on Tuesday September 18, 2018

SAN DIEGO, Sept. 18, 2018 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics company, developing targeted therapies for the treatment of leukemias, lymphomas and solid tumor cancers, today announced it will be featured as a presenting company at The MicroCap Conference that is being held on October 1st and 2nd, 2018 at the Essex House in New York City. Dr. Thomas Adams, Executive Chairman of Trovagene, Inc., will provide an overview of the Company, the current status of ongoing clinical trials in Acute Myeloid Leukemia (AML) and metastatic Castration-Resistant Prostate Cancer (mCRPC), as well as anticipated near-term milestones, during the live presentation on October 2nd at 10:30 AM eastern time.  Dr. Adams and Dr. Mark Erlander, Chief Scientific Officer, will also be available to participate in one-on-one meetings with investors who are registered to attend the conference, on Monday, October 1st and Tuesday, October 2nd.


Trovagene Announces European Commission Grants Orphan Drug Designation to Onvansertib (PCM-075) for Treatment of Acute Myeloid Leukemia in Europe
Posted on Wednesday August 29, 2018

SAN DIEGO, Aug. 29, 2018 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics company, using a precision medicine approach to develop drugs for the treatment of leukemias, lymphomas and solid tumor cancers, today announced that the European Commission (EC) has endorsed the positive opinion of the Committee for Orphan Medicinal Products (COMP) and has granted Orphan Drug Designation (ODD) for Onvansertib, a first-in-class, 3rd generation, oral and highly-selective Polo-like Kinase 1 (PLK1) inhibitor, for the treatment of patients with Acute Myeloid Leukemia (AML). "The European Commission's decision to grant orphan drug designation to Onvanersertib for the treatment of AML is a key regulatory milestone that will further facilitate our clinical development program," said Dr. Thomas Adams, Executive Chairman of Trovagene.


Trovagene Announces Participation at the 20th Annual Rodman & Renshaw Global Investment Conference in New York City September 4-6, 2018
Posted on Thursday August 23, 2018

SAN DIEGO, Aug. 23, 2018 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics company, developing targeted therapies for the treatment of leukemias, lymphomas and solid tumor cancers, today announced it will be featured as a presenting company at the 20th Annual Rodman & Renshaw Global investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held on September 4-6, 2018 at the St. Regis New York Hotel in New York City. Dr. Thomas Adams, Executive Chairman of Trovagene, Inc., will provide an overview of the Company's business during the live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.